Alternant(e) – Market Access

Résumé Du Poste:

Rattaché(e) à un membre de l’équipe Market Access France/BeLux, l’Alternant(e) Market Access participera au développement et déploiement de la stratégie d’accès au marché en France et BeLux.

L’Alternant(e) rejoindra une filiale France/BeLux à taille humaine et aura l’opportunité d’être exposé à des projets variés et transverses.

Principales Responsabilités:

• Analyses de prix, remboursement et benchmarking
• Participation au développement de dossiers d’accès au marché en France, BeLux
• Participation au développement de modèles économiques
• Evaluation de risques et opportunités
• Veille concurrentielle, environnementale et règlementaire des politiques de santé

Qualifications / Profil Recherché:

• Formation scientifique (Ingénieur, Pharmacien, Médecin), actuellement en Master Market Access / medico-économique
• Maitrise de l’anglais oral et écrit
• Capacité d’analyse et synthèse d’information
• Proactif(ve), rigoureux(se), curieux(se) et esprit d’équipe

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

AstraZeneca requires all US employees to be fully vaccinated for COVID-19 but will consider requests for reasonable accommodations as required by applicable law.

AstraZeneca embraces diversity and equality of opportunity. We are committed to building an inclusive and diverse team representing all backgrounds, with as wide a range of perspectives as possible, and harnessing industry-leading skills. We believe that the more inclusive we are, the better our work will be. We welcome and consider applications to join our team from all qualified candidates, regardless of their characteristics. We comply with all applicable laws and regulations on non-discrimination in employment (and recruitment), as well as work authorization and employment eligibility verification requirements.